TranScrip Partners Announce US Expansion

Fri Apr 5, 2013 7:17am EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130405:nBw055265a

TranScrip Partners, the cutting edge contract organisation, announces opening of
US office to better service global client base 
PHILADEPHIA--(Business Wire)--
TranScrip Partners, the rapidly growing, cutting-edge contract organisation
today announced the formation of its US office, TranScrip Partners (USA) LLC.
The US branch of TranScrip Partners will be led by Glenn Tillotson, a
pharmaceutical expert with 25 years` industry experience and a successful track
record in drug development and life cycle management. The expansion of EU-based
TranScrip Partners to the US follows the opening of offices in Australia late
last year. The launch of the US office marks an important milestone in the
expansion of TranScrip Partners. "Establishing TranScrip`s presence in the US
will allow us to better support our clients and their global drug development
programmes and will add to the depth and breadth of our expertise in drug
development and commercialisation", said TranScrip`s Managing Partner Dr Flic
Gabbay.

http://mms.businesswire.com/bwapps/mediaserver/ViewMedia?mgid=364203&vid=4
Glenn Tillotson, Senior Partner, US Office Lead, TranScrip Partners (Photo:
Business Wire)

TranScrip Partners supports biopharmaceutical product development and life-cycle
management across a client base of over 80 companies. TranScrip Partners
challenges the traditional CRO model by offering to clients both top-level
therapeutic expertise in overcoming the hurdles encountered from translational
medicine to successful registration and market access and the staff to support
the projects. Services offered by TranScrip Partners include development and
market positioning strategies for early molecules as well as tailored support in
drug development, medical affairs, pharmacovigilance, regulatory and medical
writing during pre and post-approval. 

The unique "one-stop shop", character of its organisational model, offers an
innovative solution to managing the ever increasing costs of fixed overheads in
Pharmaceutical R&D. 

TranScrip Partners is a rapidly growing cutting-edge contract organisation that
supports biopharmaceutical product development and life cycle management.
TranScrip Partners are strategic thinkers that do, and doers who think
strategically. 

Working for more than 80 companies across four continents, TranScrip challenges
the traditional CRO model by championing medicinal products and overcoming the
hurdles encountered from translational medicine to successful registration and
market access.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130405005265/en/

USA:
Glenn S Tillotson PhD
TranScrip Partners (USA) LLC
Tel: 610 383 5705 office
Cell: 858 361 3613
Email: glenn.tillotson@transcrip-partners.com
or
UK Headquarters:
Leona Brunt
TranScrip Partners LLP
Tel: +44 1189 637846
Fax: +44 1189 637497
Email: leona.brunt@transcrip-partners.com
Web: www.transcrip-partners.com
Twitter: @TranScripPtnr

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.